Appian Upgrades Low-Code Platform with Intelligent and Automatic CPU Parallelization
RESTON, Va., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN), a leading Low-Code and Business Process Management platform provider, announced today the latest version of the Appian platform with patent pending intelligent and automatic parallelization for multi-core processing. This extends Appian's market leading Low-Code design experience, allowing Appian customers to capture complex rule and interface logic in a visual and intuitive design experience that does not require learning complex coding. Appian now stands as the only leading Low-Code Platform to offer automatic parallelization, with competing Low-Code vendors still requiring customers to develop in 3GL programming languages to take advantage of parallel computing.
Appian's latest innovation removes all complexity with programming for parallel computing - a computer science programming technique allowing a computation with many calculations to be carried out simultaneously. The upgrades intelligently analyze the design of a customer's software application built in Appian and automatically optimizes the code for parallelization across multiple CPU cores. Traditionally, developers must manually write code in 3GL development tools to take advantage of multi-core CPUs. Furthermore, as the number of CPU cores increases over time, from 4 to 16 and now 32 cores or more, writing code that takes maximum advantage of these cores becomes increasingly challenging.
Enterprises today increasingly require parallel computing to deliver the performance required for their complex business applications. Scenarios within Appian Records that retrieve data from multiple data sources in a single view can now be executed in parallel leading to large application performance gains. Preliminary testing by Appian has shown application performance has increased by as much as 300% in applications with multiple I/O operations.
"Automatic parallelization of a sequential program has long been considered the holy grail of parallel computing in computer science," said Michael Beckley, Chief Technology Officer with Appian. "Appian has achieved this through our patented SAIL engine by implementing intelligent analysis of a customer's algorithms. Through this, we can avoid common issues with parallel computing, such as race conditions, while also optimizing the execution of the sequential logic in parallel."
In addition, this release introduces a number of key features that accelerate a customer's time to solution as well as deliver compelling web and mobile user experiences. This includes:
- Improved charting in reports and linking controls
- Fast export to Microsoft Excel from Appian Reports
- Support for the latest iPhone 8 / 8 Plus and iPhone X running iOS 11 and Android 8 mobile devices
- Simplified integration design for connecting to common systems
- Accelerated interface design for building rich user experiences
Beckley continued, "Appian has always believed in delivering a low-code platform that allows our customers to deliver powerful business applications with ease. Our customers have already seen a 10x to 20x increase in the speed to deliver new digital solutions, and now with automatic parallelization, their applications are on par with the most sophisticated solutions custom built in traditional programming languages."
The latest release of the Appian platform will be available to Appian customers and partners on November 17th, 2017. Appian will also be featuring this release with automatic parallelization at the upcoming developer conferences in Las Vegas, Nevada including Amazon AWS Re:Invent on November 27th to December 1st and Gartner Application Strategies & Solutions Summit on December 4th to December 6th.
This press release includes forward-looking statements. All statements contained in this press release other than statements of historical facts, including, without limitation, statements regarding the results obtained by customers using the Appian low-code platform, the timing of the latest release of the Appian platform and the intent to feature the release at upcoming developer conferences, are forward-looking statements. The words "anticipate," believe," "continue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward-looking statements. Appian has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Appian believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, including, without limitation, risks related to market acceptance of the Appian platform, risks related to customer satisfaction with the Appian platform, customer renewals and expansion of customer use of the platform, Appian's ability to release enhanced versions of its platform on a timely basis, and the risks and uncertainties set forth in the "Risk Factors" section of Appian's prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on May 26, 2017, and subsequent reports that Appian has filed with the Securities and Exchange Commission. Moreover, Appian operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Appian's management to predict all risks, nor can Appian assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Appian may make. In light of these risks, uncertainties and assumptions, Appian cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Appian is under no duty to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations, except as required by law.
Appian provides a leading low-code software development platform that enables organizations to rapidly develop powerful and unique applications. The applications created on Appian's platform help companies drive digital transformation and competitive differentiation. For more information, visit www.appian.com.
Director of Media Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Appian Corporation via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
SEMAFO Mourns Passing of Board Chairman Jean Lamarre23.11.2017 22:01 | Pressmeddelande
MONTREAL, Nov. 23, 2017 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF) (OMX:SMF) announces with sadness the passing of Mr. Jean Lamarre, Chairman of the Board of Directors of the Corporation, on November 22, 2017 following a short illness. Mr. Lamarre joined the Corporation's Board of Directors in 1997 and was appointed Chairman of the Board in 2000, a position he held until his demise. "Jean made an indelible mark on SEMAFO, both in terms of his corporate governance expertise and his 45 years of experience in Africa," said President and CEO Benoit Desormeaux. "Over his 20-year tenure with SEMAFO, he brought unique insight, business acumen and leadership to the Corporation as it transitioned from an exploration company to a junior gold producer. He did this, always without compromising his values: the integrity of the Corporation, his deep love for Africa and its people, and his priority to SEMAFO's long-term sustainability. On behalf of SEMAFO's Board of Directors, management and employe
Premier to join industry leaders at BDA London forum23.11.2017 21:39 | Pressmeddelande
HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- Premier David Burt will join more than two-dozen Bermuda executives in a multi-industry forum being held in London next week to showcase the breadth of expertise and advantages offered by the island's global business market. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/78c5ac53-07f7-4dd8-83e0-753ea5b4c80b Organised by the Bermuda Business Development Agency (BDA), the one-day event Tuesday, November 28 at ME London has attracted over 200 registrants. It will feature top regulatory and industry leaders in moderated discussion panels covering re/insurance, captive insurance, insurance-linked securities, asset management, family offices, and trust and private-client business. A networking reception will wrap the event in the evening. "The government supports the Bermuda Business Development Agency in this awareness-raising event that offers such gre
Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring23.11.2017 14:00 | Pressmeddelande
SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research. Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement
LeoVegas AB: Valberedning utsedd i LeoVegas inför årsstämma 201823.11.2017 11:50 | Pressmeddelande
Enligt de principer för valberedning i LeoVegas AB (publ) ("Bolaget" eller "LeoVegas") som antogs på årsstämman den 17 maj 2017 ska valberedningen bestå av fyra ledamöter utsedda av de tre största aktieägarna per den 30 september 2017, jämte styrelsens ordförande. Baserat på ovanstående har valberedningen inför årsstämman 2018 fastställts till att bestå av följande personer som tillsammans representerar cirka 23 procent av antalet aktier och röster i Bolaget per den 30 september 2017: Anders Fast, valberedningens ordförande och utsedd av Gustaf Hagman Joachim Spetz, utsedd av Swedbank Robur Fonder Dan-Alp Lindberg utsedd Robin Ramm-Ericson Mårten Forste, styrelseordförande Valberedningens förslag kommer att presenteras i kallelsen till årsstämman 2018 samt på bolagets hemsida, www.leovegasgroup.com.
LeoVegas AB: Nomination committed appointed for LeoVegas ahead of 2018 Annual General Meeting23.11.2017 11:50 | Pressmeddelande
In accordance with the principles for appointment of a nomination committee of LeoVegas AB (publ) ("the Company" or "LeoVegas") that were adopted by the Annual General Meeting on 17 May 2017, the Nomination Committee shall consist of four members appointed by the three largest shareholders as at 30 September 2017, together with the Chairman of the Board. Based on the above, the Nomination Committee ahead of the 2018 Annual General Meeting has been determined to consist of the following persons, who represent approximately 23% of the number of shares and votes in the Company as per 30 September 2017: Anders Fast, Nomination Committee chair, representing Gustaf Hagman Joachim Spetz, representing Swedbank Robur Fonder Dan-Alp Lindberg, representing Robin Ramm-Ericson Mårten Forste, Chairman of the Board The No
Hemcheck Sweden AB: Viktigt patent beviljat av PRV23.11.2017 09:00 | Pressmeddelande
PRESSMEDDELANDE Viktigt patent beviljas av PRV PRV, det svenska patent och registreringsverket, meddelar att HemChecks patentansökan gällande bolagets blodseparationsteknik kommer att beviljas för Sverige den 19 december 2017. Patentets publiceringsnummer kommer att bli 539853. -För HemCheck är patentet strategiskt mycket viktigt, eftersom det innefattar vår teknik för blodseparation. Det skyddar den teknik som gör att en ej definierad blodvolym kan användas i vårt engångstest och det är just det som gör vårt hemolystest så unikt, enkelt och användarvänligt - och dessutom mycket snabbt. I kombination med övriga patent har vi nu ett mycket bra skydd för den metod som HemChecks affärsidé i grunden bygger på, säger vd Annelie Brolinson i en kommentar. En internationell patentansökan har lämnats in för att söka skydd på övriga viktiga marknader. För ytterligare information, kontakta: Hemcheck Sweden AB
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum